In-Home HIV Test Could Be Hit, Barrington Research Upgrades OraSure Technologies (OSUR) to Outperform

August 9, 2012 9:58 AM EDT Send to a Friend
Get Alerts OSUR Hot Sheet
Price: $8.33 --0%

Rating Summary:
    12 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade OSUR Now!
Join SI Premium – FREE
Barrington Research upgraded OraSure Technologies (NASDAQ: OSUR) from Market Perform to Outperform with a price target of $12.50.

"OSUR achieved a major milestone this quarter when it obtained the recent FDA approval of its OraQuick® In-Home HIV Test. The company will be the first to market with the only rapid HIV test approved for sale into the U.S. consumer marketplace. We believe this is going to be a very significant product line over the long term. We really believe this should be a $50 million business in the U.S. and we are hopeful that we see that kind of run-rate in short order given the benefits to uninfected individuals," stated today's analyst report.

For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.

Shares of OraSure Technologies closed at $9.84 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change, Upgrades

Add Your Comment